* Bausch + Lomb and Nicox announce publication of
latanoprostene bunod (LBN) ophthalmic solution 0.024 pct phase 3
study results in American journal of ophthalmology
The post BRIEF-Bausch + Lomb and Nicox announce publication of LBN ophthalmic solution 0.024% phase 3 study results appeared first on NASDAQ.